<?xml version='1.0' encoding='utf-8'?>
<document id="30361928"><sentence text="In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel."><entity charOffset="88-98" id="DDI-PubMed.30361928.s1.e0" text="Vonoprazan" /><entity charOffset="103-114" id="DDI-PubMed.30361928.s1.e1" text="Clopidogrel" /><pair ddi="false" e1="DDI-PubMed.30361928.s1.e0" e2="DDI-PubMed.30361928.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s1.e0" e2="DDI-PubMed.30361928.s1.e1" /></sentence><sentence text="It was recently proposed that CYP-mediated drug-drug interactions (DDIs) of vonoprazan with clopidogrel and prasugrel can attenuate the antiplatelet actions of the latter two drugs"><entity charOffset="76-86" id="DDI-PubMed.30361928.s2.e0" text="vonoprazan" /><entity charOffset="92-103" id="DDI-PubMed.30361928.s2.e1" text="clopidogrel" /><entity charOffset="108-117" id="DDI-PubMed.30361928.s2.e2" text="prasugrel" /><pair ddi="false" e1="DDI-PubMed.30361928.s2.e0" e2="DDI-PubMed.30361928.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s2.e0" e2="DDI-PubMed.30361928.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s2.e0" e2="DDI-PubMed.30361928.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30361928.s2.e1" e2="DDI-PubMed.30361928.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s2.e1" e2="DDI-PubMed.30361928.s2.e2" /></sentence><sentence text=" Clopidogrel is metabolized to the pharmacologically active metabolite H4 and its isomers by multiple CYPs, including CYP2C19 and CYP3A4"><entity charOffset="1-12" id="DDI-PubMed.30361928.s3.e0" text="Clopidogrel" /></sentence><sentence text=" Therefore, to investigate the possibility of CYP-based DDIs, in vitro metabolic inhibition studies using CYP probe substrates or radiolabeled clopidogrel and human liver microsomes (HLMs) were conducted in this work"><entity charOffset="143-154" id="DDI-PubMed.30361928.s4.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Reversible inhibition studies focusing on the effects of vonoprazan on CYP marker activities and the formation of the [14C]clopidogrel metabolite H4 were conducted with and without pre-incubation using HLMs"><entity charOffset="57-67" id="DDI-PubMed.30361928.s6.e0" text="vonoprazan" /><entity charOffset="118-134" id="DDI-PubMed.30361928.s6.e1" text="[14C]clopidogrel" /><pair ddi="false" e1="DDI-PubMed.30361928.s6.e0" e2="DDI-PubMed.30361928.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s6.e0" e2="DDI-PubMed.30361928.s6.e1" /></sentence><sentence text=" Time-dependent inhibition (TDI) kinetics were also measured" /><sentence text="" /><sentence text="It was found that vonoprazan is not a significant direct inhibitor of any CYP isoforms (IC50 ≥ 16 μM), but shows the potential for TDI of CYP2B6, CYP2C19, and CYP3A4/5"><entity charOffset="18-28" id="DDI-PubMed.30361928.s9.e0" text="vonoprazan" /></sentence><sentence text=" This TDI was weaker than the inhibition induced by the corresponding reference inhibitors ticlopidine, esomeprazole, and verapamil, based on the measured potencies (kinact/KI ratio and the R2 value)"><entity charOffset="91-102" id="DDI-PubMed.30361928.s10.e0" text="ticlopidine" /><entity charOffset="104-116" id="DDI-PubMed.30361928.s10.e1" text="esomeprazole" /><entity charOffset="122-131" id="DDI-PubMed.30361928.s10.e2" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.30361928.s10.e0" e2="DDI-PubMed.30361928.s10.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s10.e0" e2="DDI-PubMed.30361928.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s10.e0" e2="DDI-PubMed.30361928.s10.e2" /><pair ddi="false" e1="DDI-PubMed.30361928.s10.e1" e2="DDI-PubMed.30361928.s10.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s10.e1" e2="DDI-PubMed.30361928.s10.e2" /></sentence><sentence text=" In a more direct in vitro experiment, vonoprazan levels of up to 10 µM (a 100-fold higher concentration than the plasma Cmax of 75"><entity charOffset="39-49" id="DDI-PubMed.30361928.s11.e0" text="vonoprazan" /></sentence><sentence text="9 nM after taking 20 mg once daily for 7 days) did not suppress the formation of the active metabolite H4 or other oxidative metabolites of [14C]clopidogrel in a reversible or time-dependent manner"><entity charOffset="140-156" id="DDI-PubMed.30361928.s12.e0" text="[14C]clopidogrel" /></sentence><sentence text=" Additionally, an assessment of clinical trials and post-marketing data suggested no evidence of a DDI between vonoprazan and clopidogrel"><entity charOffset="111-121" id="DDI-PubMed.30361928.s13.e0" text="vonoprazan" /><entity charOffset="126-137" id="DDI-PubMed.30361928.s13.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.30361928.s13.e0" e2="DDI-PubMed.30361928.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s13.e0" e2="DDI-PubMed.30361928.s13.e1" /></sentence><sentence text="" /><sentence text="The body of evidence shows that the pharmacodynamic DDI reported between vonoprazan and clopidogrel is unlikely to be caused by the inhibition of CYP2B6, CYP2C19, or CYP3A4/5 by vonoprazan"><entity charOffset="73-83" id="DDI-PubMed.30361928.s15.e0" text="vonoprazan" /><entity charOffset="88-99" id="DDI-PubMed.30361928.s15.e1" text="clopidogrel" /><entity charOffset="178-188" id="DDI-PubMed.30361928.s15.e2" text="vonoprazan" /><pair ddi="false" e1="DDI-PubMed.30361928.s15.e0" e2="DDI-PubMed.30361928.s15.e0" /><pair ddi="false" e1="DDI-PubMed.30361928.s15.e0" e2="DDI-PubMed.30361928.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s15.e0" e2="DDI-PubMed.30361928.s15.e2" /><pair ddi="false" e1="DDI-PubMed.30361928.s15.e1" e2="DDI-PubMed.30361928.s15.e1" /><pair ddi="false" e1="DDI-PubMed.30361928.s15.e1" e2="DDI-PubMed.30361928.s15.e2" /></sentence><sentence text="" /></document>